It’s time for a new kind of CDMO.

At Molecular Pharming Solution, we specialize in delivering top-tier services that drive innovation and quality in the biotech/pharmaceutical industry - using a plant based solution.

Curious to test us out?

We know our plant-based system is new. We are eager to provide you with testable amounts of your target protein to validate the platform's efficacy.

Ready to scale up?

We've got you covered. 5 million vaccine doses per month capacity.

Molecular Pharming Solution Stands Out:

Fast Expression

Go from concept to purified protein in 7–10 days, empowering rapid iteration and data-driven refinement, giving you the edge.

Human-compatible glycosylation

Our ΔXF Nicotiana benthamiana lines yield proteins with human-compatible glycosylation, ensuring functionality comparable to mammalian expression systems.

Production Capacity

Our Current Good Manufacturing grade facility is capable of producing up to 5 million doses of vaccine per month, or 240Kg of biomass per month.

Our platform is widely effective

We have produced

Other examples from published literature

*These examples are provided for educational purposes to highlight the range of proteins expressed in plant-based systems. They do not represent work performed by Molecular Pharming Solution.

Human IL-15 (Fc-fusion)

Pembrolizumab–IL-15Rα–IL-15 fusion (anti-PD-1 × cytokine complex)

Atezolizumab (anti-PD-L1)

Anti-PD-L1 mAb (Atezolizumab biosimilar)

Nivolumab (anti-PD-1)

Anti-CTLA-4 (2C8)

Anti-HIV Fc-fusion proteins (Gutierrez-Valdes et al., 2024)

Human IL-1 Beta

Human GM-CSF

Human Tumor Necrosis Factor Alpha

Fibroblast Growth Factor 2

Human Serum Albumin

SARS-CoV-2 RBD-Fc (WT/Alpha/Beta variants)

Soluble HIV-1 Env gp140 antigen (Margolin et al., 2019)

Improvement of expression of HIV gp140 via co-expression with human calreticulin (Margolin et al., 2020)

HIV-1 Nef protein (Lombardi et al., 2009)

Co-expression of SARS-CoV-2 nucleocapsid (N) + RBD (Mamedov et al., 2021)

SARS-CoV-2 spike trimer vaccine (Song et al., 2022)

SARS-CoV-2 RBD + influenza M2e flagellin fusion (Mardanova et al., 2022)

Human butyrylcholinesterase (Schneider et al., 2013)

Butyrylcholinesterase oligomerization / subcellular location (Alkanaimsh et al., 2016)

Ready to be your CDMO!

Stage 1 - Proof of Concept in Plant System

Goal

Demonstrate the expression and basic activity of your target protein in a plant-based system, with the option to compare and select the best candidate from 2–5 constructs for further development.

Key Activities

Codon optimization & vector construction
Transient expression in N. benthamiana
Small-scale purification
Basic functional assay
Parallel expression & analysis of multiple candidates for yield/activity comparison

Deliverables

Vector map(s) & sequences
Yield data for each candidate
SDS-PAGE / Western blot
Functional assay results
Comparative table with recommendations for lead selection
Technical report

Stage 2 - Process Optimization & Research-Grade Production

Goal

Improve yield, purity, and reproducibility while supplying research-grade protein suitable for preclinical work.

Key Activities

Optimize expression conditions & harvest timing
Scale-up in greenhouse/plant factory
Purification process development
Analytical method development

Deliverables

Process development report
Analytical data (purity, MW, glycosylation, endotoxin)
Stability data
Research-grade protein + CoA

Stage 3 - Preclinical / GLP Toxicity Supply

Goal

Produce GLP-compliant material for toxicology and efficacy studies.

Key Activities

Pilot-scale controlled production
Purification under GLP conditions
Stability testing- Supply to GLP tox CRO

Deliverables

GLP-compliant batch CoA
Batch record
Stability report
Material for tox studies”

Stage 4A - GMP Phase 1 Supply

Goal

GMP production of drug substance/product for first-in-human trial.

Key Activities

Tech transfer to GMP facility
GMP batch production
Fill/finish
GMP release testing
Stability program start

Deliverables

GMP batch CoA
GMP batch records
Validation reports for CMC phase 1
Initial stability data
Material for clinical trial phase 1

Stage 4B - Regulatory Support

Goal

Prepare CMC & plant-specific documentation for IND/CTA

Key Activities

Compile CMC section
Respond to agency queries

Deliverables

CMC module for IND/CTA
Risk assessment report
Regulatory Q&A support

We Are Molecular Pharming Solution

As the Contract Development and Manufacturing Organization (CDMO) of the Baiya Phytopharm ecosystem, we were founded with the vision of making fast and affordable recombinant protein expression accessible to companies and researchers around the globe.